- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03623503
Clinical Criteria for a Pathogen in Term Newborn Suspected of Neonatal Sepsis (IMF-NN)
August 8, 2018 updated by: Centre Hospitalier Universitaire, Amiens
Neonatal early onset sepsis (EOS) diagnosis is difficult due to lack of sensivity and specificity markers.
The investigators conduced a restrospectif study to all term born infants born between 1 january and 31 December 2013 and hospitalized for suspect EOS.
The presence of neonatal symptoms at birth appears to be a useful clinical marker of probable neonatal EOS.
Study Overview
Detailed Description
neonatal early onset spesis (EOS) remains animportant etiology of neonatal morbidity and mortality.
Neonatal early onset sepsis (EOS) diagnosis is difficult due to lack of sensivity and specificity markers.
Diagnosis is difficults due to lack of sensivity and specificity markers.
The investigators conduced a restrospectif study to all term born infants born between 1 january and 31 December 2013 and hospitalized for suspect EOS.The objective of the study was to identify early clinical signs in newborn infants with suspected neonatal sepsis to differentiate a likely infection with pathogen bacteria in the gastric suction culture.The presence of neonatal symptoms at birth appears to be a useful clinical marker of probable neonatal EOS.
Study Type
Observational
Enrollment (Actual)
58
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 day and older (ADULT, OLDER_ADULT, CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Children born between 1 January and 31 December 2013 and hospitalized in the neonatology department for suspicion of MFIs.
Presence of early clinical signs, ie before 72 hours of life.
Description
Inclusion Criteria:
- Children born at the University Hospital Center in Amiens between 1 January and 31 December 2013 and hospitalized in the neonatology department for suspicion of MFIs
Exclusion Criteria:
- Child born before 37 weeks of amenorrhea and / or having a failure in the birth room requiring immediate transfer to neonatal resuscitation or intensive care neonatology
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
first group
Observational study of 25 newborn with a likely EOS
|
|
second group
Observational study of v33 newborn with a possible EOS
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
clinical signs in newborn infants
Time Frame: 1 year
|
The objective of the study was to determine early clinical signs in newborn infants with suspected neonatal sepsis to differentiate a likely infection with pathogen bacteria in gastric suction culture.The investigators conduced a retrospective study and all term newborn infant born between 1 january and 31 december 2013 and hospitalized for suspected EOS were included.From the computerized medical file, which is filled in exhaustively, the data were given in the form of continuous values or in the form of a category: maternal age, gestationality, delivery period, delivery method, childbirth administration of maternal antibiotherapy.
the parameters at birth were recorded in the same way: sex of the newborn, measurements of birth (birth weight, height, cranial perimeter).
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
February 21, 2016
Primary Completion (ACTUAL)
July 12, 2017
Study Completion (ACTUAL)
July 12, 2017
Study Registration Dates
First Submitted
August 2, 2018
First Submitted That Met QC Criteria
August 8, 2018
First Posted (ACTUAL)
August 9, 2018
Study Record Updates
Last Update Posted (ACTUAL)
August 9, 2018
Last Update Submitted That Met QC Criteria
August 8, 2018
Last Verified
August 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RNI2016-18- PrTourneux
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Newborn Sepsis
-
Hamilton Health Sciences CorporationCompletedInfection | Sepsis NewbornCanada
-
Zekai Tahir Burak Women's Health Research and Education...UnknownSepsis of the NewbornTurkey
-
Mansoura University Children HospitalCompleted
-
Universitas Sebelas MaretCompletedSepsis NewbornIndonesia
-
Indian Council of Medical ResearchKing George's Medical University; Lady Hardinge Medical College; Postgraduate... and other collaboratorsCompletedRecurrence | Anti-bacterial Agents | Neonatal SEPSIS | Infant, NewbornIndia
-
BioMérieuxInstitut de Recherche pour le Developpement; Centre National de la Recherche... and other collaboratorsCompletedMalaria | Sepsis Newborn | Immune Responses
-
Drugs for Neglected DiseasesUniversiteit Antwerpen; PENTA Foundation; St George's, University of LondonCompletedNeonatal SEPSISBangladesh, Uganda, Thailand, South Africa, Italy, Greece, India, Brazil, China, Kenya, Vietnam
-
Assiut UniversityUnknown
-
Assiut UniversityUnknown
-
Sisli Hamidiye Etfal Training and Research HospitalCompleted
Clinical Trials on Observational study
-
Taysha Gene Therapies, Inc.Withdrawn
-
AstraZenecaRecruitingNon-Small Cell Lung CancerUnited States
-
University of ManitobaCompletedObesity | Pregnancy | Cesarean SectionCanada
-
University of Castilla-La ManchaRecruitingKnee OsteoarthritisSpain
-
AstraZenecaRecruiting
-
Drexel UniversityCompletedOsteoporosisUnited States
-
The Aurum Institute NPCKarolinska Institutet; Ludwig-Maximilians - University of Munich; University... and other collaboratorsUnknownRespiratory Tract Infections | Tuberculosis, PulmonaryMozambique, South Africa, Tanzania, Gambia
-
Oslo University HospitalThe Research Council of NorwayRecruitingMesothelioma | Pseudomyxoma Peritonei | Colorectal Carcinoma | Ovarian CarcinomaNorway
-
Oslo University HospitalThe Research Council of NorwayActive, not recruiting
-
AstraZenecaDaiichi Sankyo, Inc.CompletedBreast CancerUnited States, Germany, Italy, Korea, Republic of, United Kingdom, Portugal, Australia, Japan, Canada, France